192 related articles for article (PubMed ID: 36094043)
1. Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.
Reichstein D; Brock A; Lietman C; McKean M
Curr Opin Ophthalmol; 2022 Nov; 33(6):585-590. PubMed ID: 36094043
[TBL] [Abstract][Full Text] [Related]
2. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract][Full Text] [Related]
3. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
Liu AW; Wei AZ; Maniar AB; Carvajal RD
Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
[TBL] [Abstract][Full Text] [Related]
4. [DEVELOPMENT AND CHALLENGES IN TREATMENT OF UVEAL MELANOMA].
Zloto O; Vishnevskia-Dai V; Moisseiev J; Fabian ID
Harefuah; 2018 Feb; 157(2):95-98. PubMed ID: 29484864
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches to the Systemic Management of Uveal Melanoma.
Khan S; Carvajal RD
Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
[TBL] [Abstract][Full Text] [Related]
6. Advances in the clinical management of uveal melanoma.
Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S
Nat Rev Clin Oncol; 2023 Feb; 20(2):99-115. PubMed ID: 36600005
[TBL] [Abstract][Full Text] [Related]
7. Tebentafusp: First Approval.
Dhillon S
Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
[TBL] [Abstract][Full Text] [Related]
8. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
9. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
10. Updates in the Management of Uveal Melanoma.
Barbi M; Carvajal RD; Devoe CE
Cancer J; 2024 Mar-Apr 01; 30(2):92-101. PubMed ID: 38527262
[TBL] [Abstract][Full Text] [Related]
11. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
13. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
14. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in uveal melanoma treatment.
Álvarez-Rodríguez B; Latorre A; Posch C; Somoza Á
Med Res Rev; 2017 Nov; 37(6):1350-1372. PubMed ID: 28759124
[TBL] [Abstract][Full Text] [Related]
16. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract][Full Text] [Related]
17. Uveal melanoma: laboratory advances and new frontiers in patient care.
Xu TT; Moser JC; Dalvin LA
Curr Opin Ophthalmol; 2021 May; 32(3):301-308. PubMed ID: 33606406
[TBL] [Abstract][Full Text] [Related]
18. Metastatic uveal melanoma: The final frontier.
Rantala ES; Hernberg MM; Piperno-Neumann S; Grossniklaus HE; Kivelä TT
Prog Retin Eye Res; 2022 Sep; 90():101041. PubMed ID: 34999237
[TBL] [Abstract][Full Text] [Related]
19. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
Hua G; Carlson D; Starr JR
J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
